India BSE NSE Trading Suspension Orders — February 11, 2026

Routine unaudited standalone/consolidated Q3/9M FY26 results filing via BSE with neutral sentiment and low risk, no disclosed adverse trends or metrics

Board approval of Q3/9M FY26 results without noted issues, dividends, or corporate actions under SEBI LODR, low materiality

Investor presentation released post-results under Regulation 30, signaling transparency absent governance flags

Standard Q3 FY26 unaudited results disclosure via BSE, neutral sentiment, lowest materiality (1/10), no quantitative concerns

Absence of trading suspension post-results release despite stream focus, contrasts IIRM, low risk across three filings

Continued trading uninterrupted after Q3 results, no surveillance triggers unlike peers in suspension stream

4/5 filings show routine compliance with no period declines, insider sales, or guidance cuts disclosed

No risk factors beyond data absence, stable vs. delisting peers, potential relative outperformance

Materiality 1/10 signals minimal market impact, supports holding amid sector stability

Trading suspension tied to CSE delisting announcement under Regulation 30, halts all activity

Bearish sentiment with high risk/materiality (9/10), no resolution timeline disclosed

Voluntary delisting uncertainty reduces liquidity, no financial/operational metrics to counter

BSE trading fully suspended as of Feb 11, 2026, linked to CSE delisting PA, halts buy/sell

Voluntary delisting from CSE with no duration, surveillance, or financial impact details, liquidity erosion risk

SEBI LODR Reg 30 announcement lacks timeline/resolution, potential prolonged halt

No specific financial metrics, YoY/QoQ trends, or ratios disclosed, limits trend assessment

Absence of quantitative data in Q3/9M FY26 filing despite routine nature

No period comparisons, insider activity, or metrics in Q3 results, routine but opaque

No dividends, capex, or trends post-approval, per filing summary

Investor presentation lacks material details, leadership, or events

No forward-looking, capital allocation, or operational metrics across 4 filings, hinders outperformance gauge

1/5 high-risk event, but lack of cross-company metrics prevents relative risk benchmarking

Low-risk Q3/9M results across 3 filings suggest operational continuity, buy dips if market misprices auto sector

1/10 materiality Q3 filing indicates negligible disruption, alpha from stability vs. suspension peers

M&M and Ashok Leyland filings confirm no trading issues post-results, relative value play vs. delisted names

Timely board outcome without flags, potential for positive full results details

Investor presentation release enhances visibility, monitor for bullish metrics

High materiality suspension/delisting bearish signal, potential downside if liquidity dries further

Undisrupted trading amid stream focus, pair trade long auto vs. suspended small-caps

Absence of negatives in summary, alpha if full filings reveal YoY growth beats

M&M (3 filings) and Ashok Leyland both neutral/low risk, undervalued if suspensions contagion fears rise

Voluntary CSE delisting may offer exit premium, watch PA details for takeover hints

4/5 filings (M&M x3, Ashok Leyland) are neutral Q3 FY26 results with low risk/materiality, no suspensions signal stability vs. broader market halts [IMPLICATION: Prefer autos for low volatility]

Only 1/5 (IIRM Holdings) shows trading halt/delisting, no auto sector pattern, contrasts large-cap resilience [IMPLICATION: Sector rotation away from microcaps]

All filings lack YoY/QoQ trends, insider data, guidance; autos more prolific (4 filings) but equally opaque [IMPLICATION: Await full reports for metric synthesis]

4/5 neutral (low materiality 1-2/10), 1 bearish high-risk; no margin compression or growth deceleration patterns evident [IMPLICATION: Absence of negatives supports base case holds]

SEBI LODR Reg 30 invoked in M&M update and IIRM suspension, routine for autos, punitive for delisting [IMPLICATION: Monitor Reg 30 for early halt signals]

Autos maintain trading post-results, IIRM fully suspended; no capital allocation/dividend trends to assess health [IMPLICATION: Favor liquid large-caps in halt-prone streams]

Monitor BSE suspension resolution and CSE voluntary delisting progress, no disclosed timeframe [Ongoing from Feb 11, 2026]

Watch for BSE announcements on halt triggers/financial impacts post-Reg 30 PA [Post Feb 11, 2026]

Track detailed YoY/QoQ revenue, margins, ratios from unaudited results/investor presentation [Immediate post Feb 11]

Potential Q3 FY26 conference call for guidance, insider views absent in filings [Within days of Feb 11, 2026]

Await full disclosure of period comparisons, operational metrics undisclosed in summary [Post Feb 11, 2026]

Watch for follow-up on dividends, buybacks, M&A absent in outcome [Next board/AGM]

No transactions/pledges reported; monitor NSE/BSE for post-results buying/selling patterns [Next 1-2 weeks]

No AGMs/record dates listed; track BSE for additional suspensions in similar holdings firms [Feb 2026 onward]